ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
unknown
📅 Published: 2026-01-22 17:03
📰 Source: Yahoo
📝 Words: 26
📝 Article Content
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.
📄 Summary
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-01-29 16:37:52
Updated At:
2026-01-29 16:37:52
Scraping Job ID:
N/A
Stock Mentions:
ABBV - AbbVie Inc.
Relevance: N/A
MRK - Merck & Co. Inc.
Relevance: N/A